AMZ 0026

Drug Profile

AMZ 0026

Alternative Names: Abavca; AMZ 0026-H; AMZ-0026; AZC 0027; Perthon

Latest Information Update: 18 Sep 2015

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advanced Plant Pharmaceuticals
  • Developer Amazon Biotech
  • Class Antivirals
  • Mechanism of Action Immunomodulators; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported HIV infections
  • Discontinued Breast cancer; Coronavirus infections; Lyme disease

Most Recent Events

  • 18 Sep 2015 No recent reports on development identified - Phase-I/II for HIV infections in USA and India (PO)
  • 16 Mar 2012 Phase-I/II development is ongoing in USA
  • 27 Feb 2012 Discontinued - Preclinical for Breast cancer in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top